Activins and BMPs: The yin and yang of diffuse midline gliomas.

Activin B-ACVR2A signaling drives growth in diffuse midline gliomas, with a new patient-derived organoid model revealing a promising triple intrathecal therapy.

• Why it matters: Diffuse midline gliomas are difficult to study and treat due to limited models and understanding of their biology. Addressing this gap could lead to more effective therapies for these aggressive tumors.
• What they did: Xie et al. created a patient-derived brainstem glioma organoid platform and identified Activin B-ACVR2A signaling as a key promoter of tumor growth, testing a triple intrathecal therapy to target it.
• The result: The findings suggest that inhibiting Activin B-ACVR2A signaling with the proposed therapy could offer a new, effective treatment approach for DMGs, improving patient outcomes.